Dr. Ralph Grobecker to become Managing Director of STADA’s OTC segment

  • 4/24/2017
  • Press Release

Bad Vilbel, April 24, 2017 –

STADA Arzneimittel AG is further strengthening its branded products business on the personnel side. Dr. Ralph Grobecker will become the future Managing Director at STADA GmbH. In this role, he will have responsibility for the entire German OTC product range and will report directly to Dieno George, Executive Vice President Brands. He will join the STADA group on May 1, 2017.

Dr. Grobecker has decades of experience in the German pharmaceutical market and has developed outstanding expertise in the field of OTC medication in the various positions he has held. Since 2006, Dr. Grobecker worked at Merck, initially in the finance area as Head of R&D Controlling for Rx products and, from 2010 as CFO for the self-medication unit at Merck in Germany. From 2012 he assumed management responsibility for the German OTC business and was also responsible for the DACH region from last year. Prior to that, he worked for McKinsey & Company in the healthcare sector, among other positions.

“We are very happy that we have been able to attract a proven expert like Dr. Ralph Grobecker to run our brands business. With his broad background of experience and deep knowledge of the German OTC market, he will significantly strengthen our business and will help us to further develop our successful brands and expand our strong market position”, says Dieno George.   

About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. Worldwide, STADA is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2016, STADA achieved adjusted Group sales of Euro 2,167.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 398 million and adjusted net income of Euro 177.3 million. As of December 31, 2016, STADA employed 10,900 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de